Moody Aldrich Partners LLC grew its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 31.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 398,475 shares of the company's stock after acquiring an additional 95,413 shares during the quarter. Moody Aldrich Partners LLC owned 0.26% of Wave Life Sciences worth $4,929,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company's stock valued at $37,000 after purchasing an additional 856 shares during the period. Mackenzie Financial Corp increased its holdings in Wave Life Sciences by 13.6% in the 2nd quarter. Mackenzie Financial Corp now owns 15,887 shares of the company's stock worth $79,000 after buying an additional 1,905 shares during the period. Kraematon Investment Advisors Inc. increased its holdings in Wave Life Sciences by 24.3% in the 4th quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company's stock worth $246,000 after buying an additional 3,885 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Wave Life Sciences by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 139,790 shares of the company's stock valued at $698,000 after acquiring an additional 4,914 shares during the period. Finally, KBC Group NV purchased a new stake in shares of Wave Life Sciences in the 4th quarter valued at $67,000. Hedge funds and other institutional investors own 89.73% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the stock. StockNews.com cut shares of Wave Life Sciences from a "hold" rating to a "sell" rating in a report on Wednesday, November 13th. Royal Bank of Canada lifted their price objective on Wave Life Sciences from $7.00 to $15.00 and gave the company a "sector perform" rating in a research note on Monday, October 21st. Raymond James upgraded Wave Life Sciences from an "outperform" rating to a "strong-buy" rating and upped their target price for the stock from $13.00 to $22.00 in a research note on Wednesday, October 16th. B. Riley lifted their price target on Wave Life Sciences from $19.00 to $22.00 and gave the company a "buy" rating in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. upped their price objective on Wave Life Sciences from $13.00 to $17.00 and gave the stock an "overweight" rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Wave Life Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $22.22.
Read Our Latest Report on WVE
Wave Life Sciences Stock Down 4.1 %
Shares of Wave Life Sciences stock traded down $0.49 on Friday, reaching $11.57. The company's stock had a trading volume of 1,022,494 shares, compared to its average volume of 829,963. The company has a market capitalization of $1.76 billion, a P/E ratio of -10.42 and a beta of -1.07. The stock has a 50-day moving average price of $13.11 and a 200-day moving average price of $10.39. Wave Life Sciences Ltd. has a 52-week low of $3.50 and a 52-week high of $16.74.
Insider Activity at Wave Life Sciences
In other Wave Life Sciences news, CEO Paul Bolno sold 51,234 shares of the firm's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $14.32, for a total value of $733,670.88. Following the transaction, the chief executive officer now owns 217,351 shares in the company, valued at approximately $3,112,466.32. This trade represents a 19.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Chris Francis sold 36,000 shares of Wave Life Sciences stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $576,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 137,234 shares of company stock valued at $2,059,671. 29.10% of the stock is owned by company insiders.
Wave Life Sciences Profile
(
Free Report)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Further Reading
Before you consider Wave Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wave Life Sciences wasn't on the list.
While Wave Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
